These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Infliximab Therapy and the Central Nervous Demyelination in Patients with Kawasaki Disease.
    Author: Sagara Y, Muneuchi J, Shimabukuro W, Joo M, Yoshino M, Nakamura R, Yoneda T, Sugitani Y, Watanabe M, Mizushima A, Takahashi Y.
    Journal: Pediatr Infect Dis J; 2019 Aug; 38(8):e185-e187. PubMed ID: 31107420.
    Abstract:
    We performed brain magnetic resonance imaging in 14 patients with Kawasaki disease who were treated with infliximab (IFX) at 56 months of age (32-62 months of age) and 23 months (5-35 months) after IFX therapy. Magnetic resonance imaging showed no finding of the central nervous demyelination. IFX therapy is not related to central nervous demyelination in patients with Kawasaki disease.
    [Abstract] [Full Text] [Related] [New Search]